Drug Trial Radar · NCT03818828
Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)
Last checked: Nov 20, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Feb 14, 2019
Primary completion
Dec 20, 2019
Study completion Jan 28, 2020
Sponsor
- Lead sponsor
- BioTissue Holdings, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is hypothesized that application at 4-week intervals of the human umbilical cord tissue TTAX01 to the surface of a well debrided, nonhealing venous leg ulcer (VLU) will result in a high proportion of wounds showing complete healing within 12 weeks of initiating therapy. This open label pilot study provides a framework for a larger, controlled study. The purposes for conducting this study are to evaluate the functionality of the protocol and to obtain an estimate of product safety and efficacy when applied according to the protocol instructions, and measured according to the stated endpoints.
Conditions
- Venous Leg Ulcer
Interventions
TTAX01Biological
TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
Profore Compression TherapyOther
Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
Cadexomer Iodine dressingOther
During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete wound healingTime frame: 12-weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
ILD Consulting, Inc.
Carlsbad, California
UCLA Olive View
Sylmar, California
Rosalind Franklin University
North Chicago, Illinois
Advanced Foot & Ankle Center
Las Vegas, Nevada
St Luke's-Roosevelt Hospital Center
New York, New York
Carilion Clinic
Roanoke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.